Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Netflix

It's Not Too Late to Buy These Market-Beating Stocks

The shares of DexCom, Inc. (NASDAQ: DXCM) have received a $560 price target from BTIG. These are the details.

DexCom (DXCM) Stock: $560 Stock And Buy Rating

DexCom (DXCM) could produce exceptional returns because of its solid growth attributes.

Is DexCom (DXCM) a Solid Growth Stock? 3 Reasons to Think " Yes "

The availability of DexCom's (DXCM) G6 CGM System to diabetic TRICARE military members is expected to enable them to make better real-time decisions about their health.

DexCom (DXCM) G6 CGM System Now Available to TRICARE Members

The diabetes management company has launched its latest product to be sold in the United Kingdom.

Why DexCom Surged 23.6% in March

DexCom's (DXCM) upcoming launch of Dexcom ONE CGM can help people in the U.K. to manage diabetes.

DexCom's (DXCM) Upcoming Launch to Boost Diabetes Management

FIGS

1Life Healthcare

Net Promoter Scores can provide insights into customer satisfaction, and possibly lead to market-beating returns.

Customers Love These 3 Healthcare Companies

LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the new Dexcom ONE Continuous Glucose Monitoring System will launch in the United Kingdom this May. The Dexcom ONE system is an easy-to-use real-time CGM (rt-CGM) that will be more affordable and accessible for people with diabetes in the UK. Dexcom ONE is currently in review to be added to drug tariffs across the UK regions. Karen Baxter, V

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022. Management will hold a conference call to review the company's first quarter 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will

Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time

The medical device maker has already made impressive gains. A planned stock split may make shares even more attractive to investors.

DexCom Announces 4-for-1 Stock Split. Here's What Investors Need to Know.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that its Board of Directors has approved a four-for-one forward split (the “Stock Split”) of Dexcom's common stock. The Stock Split is contingent upon stockholder approval of a Restated Certificate of Incorporation that would increase the number of authorized shares of common stock from 200,000,000 to 800,000,000. If stockholders ap

Dexcom Announces Four-for-One Forward Stock Split

There's a bevy of positive signs, but trouble is lurking on the horizon.

Is DexCom a Buy?

We believe that DexCom, best known for its continuous glucose monitoring systems, currently is an attractive pick over Amedisys stock (NASDAQ: AMED), a home health and hospice company with a similar revenue base, despite Dexcom's comparatively higher valuation. DXCM stock trades at 16.3x trailing.

Stellar Sales Growth Trend Makes DexCom Stock A Wise Bet

DexCom's (DXCM) G7 CGM System receives CE Mark that can help people with diabetes in Europe, including pregnant women.

DexCom (DXCM) to Boost Diabetes Management With New Approval

Dexcom's (DXCM) G6 CGM System can help people with type 1 diabetes over two years of age through the coverage announced by the Ontario government.

Dexcom (DXCM) G6 CGM System Gets Public Coverage From Ontario

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom G7 Receives CE Mark – Next Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management

Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management

Investors should keep this healthcare stock on their radar.

DexCom to Take Its Technology International

ABIOMED

Fulgent Genetics

They have a whole lot going right, and little in the way of obstacles.

Got $5,000? 3 Growth Stocks to Buy That Could Double Your Money

Amazon

You don't have to take a big risk with either of these two stocks.

These 2 Millionaire-Maker Stocks Still Promise Solid Returns

BURNABY, British Columbia--(BUSINESS WIRE)--Ontario announces public coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program

Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program

Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.

Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION FOR DEXCOM HOSPITAL CGM SYSTEM

FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System

Up 700%, DexCom Stock Still Has Tons of Room To Run

Bull vs. Bear: DexCom Stock

Ceridian HCM Holding Inc.

EPAM Systems

Etsy

Moderna

PayPal

Teradyne

Zebra Technologies

The S&P 500 is off almost 9% for the year-to-date, but the biggest decliners in the main benchmark of U.S. equity performance are faring far, far worse. From small, somewhat obscure members of the index to the planet's best-known and biggest stocks, the S&P 500's most beaten-down names do have at least a few commonalities.

News for DexCom Stock (DXCM)